Lista de obras -

A Phase II study of (153)Sm-EDTMP and high-dose melphalan as a peripheral blood stem cell conditioning regimen in patients with multiple myeloma

scientific article published on June 2010

A multicenter phase II trial of 4'-iodo-4'deoxydoxorubicin (IDOX) in primary amyloidosis (AL).

artículo científico publicado en 2002

A phase I/II trial of reduced intensity allogeneic hematopoietic cell transplant for hematologic malignancies using cladribine, thiotepa and rabbit antithymocyte globulin

artículo científico publicado en 2012

A phase II study of bortezomib in the treatment of metastatic malignant melanoma

artículo científico publicado en 2005

A phase II trial of imatinib in patients with refractory/relapsed myeloma

artículo científico publicado en 2006

CD49d expression is an independent predictor of overall survival in patients with chronic lymphocytic leukaemia: a prognostic parameter with therapeutic potential

artículo científico publicado en 2008

Clinical and pharmacodynamic activity of bortezomib and decitabine in acute myeloid leukemia ⬇️

artículo científico publicado el 7 de mayo de 2012

Clinical response and miR-29b predictive significance in older AML patients treated with a 10-day schedule of decitabine

artículo científico publicado en 2010

Combination chemoimmunotherapy with pentostatin, cyclophosphamide, and rituximab shows significant clinical activity with low accompanying toxicity in previously untreated B chronic lymphocytic leukemia

artículo científico publicado en 2007

Combination therapy with lenalidomide plus dexamethasone (Rev/Dex) for newly diagnosed myeloma

artículo científico publicado en 2005

Combination therapy with thalidomide plus dexamethasone for newly diagnosed myeloma

artículo científico publicado en 2002

Excess BMI in Childhood: A Modifiable Risk Factor for Type 1 Diabetes Development?

artículo científico publicado en 2017

Expression of TCL-1 as a potential prognostic factor for treatment outcome in B-cell chronic lymphocytic leukemia

artículo científico publicado en 2007

Flavopiridol in patients with relapsed or refractory multiple myeloma: a phase 2 trial with clinical and pharmacodynamic end-points.

artículo científico publicado en 2006

Genome-wide methylation profiling in decitabine-treated patients with acute myeloid leukemia

artículo científico publicado en 2012

Immunoglobulin diversity gene usage predicts unfavorable outcome in a subset of chronic lymphocytic leukemia patients

artículo científico publicado en 2008

Induction of a chronic disease state in patients with smoldering or indolent multiple myeloma by targeting interleukin 1{beta}-induced interleukin 6 production and the myeloma proliferative component

artículo científico publicado en 2009

Long-term results of response to therapy, time to progression, and survival with lenalidomide plus dexamethasone in newly diagnosed myeloma

artículo científico publicado en 2007

Mcl-1 expression predicts progression-free survival in chronic lymphocytic leukemia patients treated with pentostatin, cyclophosphamide, and rituximab

artículo científico publicado en 2008

Midostaurin in patients with acute myeloid leukemia and FLT3-TKD mutations: a subanalysis from the RATIFY trial

artículo científico publicado en 2020

Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a FLT3 Mutation

artículo científico publicado en 2017

Pentostatin, cyclophosphamide, and rituximab regimen in older patients with chronic lymphocytic leukemia

artículo científico publicado en 2007

Pharmacokinetics and dose escalation of the heat shock protein inhibitor 17-allyamino-17-demethoxygeldanamycin in combination with bortezomib in relapsed or refractory acute myeloid leukemia

artículo científico publicado en 2013

Phase II study of the farnesyl transferase inhibitor R115777 in patients with advanced non-small-cell lung cancer

artículo científico publicado en 2003

Poor tolerance to high doses of thalidomide in patients with primary systemic amyloidosis

artículo científico publicado en 2003

Prospective evaluation of clonal evolution during long-term follow-up of patients with untreated early-stage chronic lymphocytic leukemia

artículo científico publicado en 2006

Response rate, durability of response, and survival after thalidomide therapy for relapsed multiple myeloma

artículo científico publicado en 2003

The activity of lenalidomide with or without dexamethasone in patients with primary systemic amyloidosis

artículo científico publicado en 2006

Validation of ZAP-70 methylation and its relative significance in predicting outcome in chronic lymphocytic leukemia

artículo científico publicado en 2014

Lista de obras de

A Phase II study of (153)Sm-EDTMP and high-dose melphalan as a peripheral blood stem cell conditioning regimen in patients with multiple myeloma

A multicenter phase II trial of 4'-iodo-4'deoxydoxorubicin (IDOX) in primary amyloidosis (AL).

A phase I/II trial of reduced intensity allogeneic hematopoietic cell transplant for hematologic malignancies using cladribine, thiotepa and rabbit antithymocyte globulin

A phase II study of bortezomib in the treatment of metastatic malignant melanoma

A phase II trial of imatinib in patients with refractory/relapsed myeloma

CD49d expression is an independent predictor of overall survival in patients with chronic lymphocytic leukaemia: a prognostic parameter with therapeutic potential

Clinical and pharmacodynamic activity of bortezomib and decitabine in acute myeloid leukemia ⬇️

Clinical response and miR-29b predictive significance in older AML patients treated with a 10-day schedule of decitabine

Combination chemoimmunotherapy with pentostatin, cyclophosphamide, and rituximab shows significant clinical activity with low accompanying toxicity in previously untreated B chronic lymphocytic leukemia

Combination therapy with lenalidomide plus dexamethasone (Rev/Dex) for newly diagnosed myeloma

Combination therapy with thalidomide plus dexamethasone for newly diagnosed myeloma

Excess BMI in Childhood: A Modifiable Risk Factor for Type 1 Diabetes Development?

Expression of TCL-1 as a potential prognostic factor for treatment outcome in B-cell chronic lymphocytic leukemia

Flavopiridol in patients with relapsed or refractory multiple myeloma: a phase 2 trial with clinical and pharmacodynamic end-points.

Genome-wide methylation profiling in decitabine-treated patients with acute myeloid leukemia

Immunoglobulin diversity gene usage predicts unfavorable outcome in a subset of chronic lymphocytic leukemia patients

Induction of a chronic disease state in patients with smoldering or indolent multiple myeloma by targeting interleukin 1{beta}-induced interleukin 6 production and the myeloma proliferative component

Long-term results of response to therapy, time to progression, and survival with lenalidomide plus dexamethasone in newly diagnosed myeloma

Mcl-1 expression predicts progression-free survival in chronic lymphocytic leukemia patients treated with pentostatin, cyclophosphamide, and rituximab

Midostaurin in patients with acute myeloid leukemia and FLT3-TKD mutations: a subanalysis from the RATIFY trial

Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a FLT3 Mutation

Pentostatin, cyclophosphamide, and rituximab regimen in older patients with chronic lymphocytic leukemia

Pharmacokinetics and dose escalation of the heat shock protein inhibitor 17-allyamino-17-demethoxygeldanamycin in combination with bortezomib in relapsed or refractory acute myeloid leukemia

Phase II study of the farnesyl transferase inhibitor R115777 in patients with advanced non-small-cell lung cancer

Poor tolerance to high doses of thalidomide in patients with primary systemic amyloidosis

Prospective evaluation of clonal evolution during long-term follow-up of patients with untreated early-stage chronic lymphocytic leukemia

Response rate, durability of response, and survival after thalidomide therapy for relapsed multiple myeloma

The activity of lenalidomide with or without dexamethasone in patients with primary systemic amyloidosis

Validation of ZAP-70 methylation and its relative significance in predicting outcome in chronic lymphocytic leukemia